Acquisitions Reshape the Bio/Pharm Services Industry - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Acquisitions Reshape the Bio/Pharm Services Industry
The quest to build critical mass and broaden capabilities has been a key factor in deal-making.


Pharmaceutical Technology
Volume 36, Issue 12


(JONATHAN EVANS/PHOTODISC/GETTY IMAGES)
The year 2012 has been an important year for acquisitions in the bio/pharmaceutical CMC (chemistry, manufacturing, and controls) contract services industry. Some of the premier names in the industry have been involved in major deals, either as buyers or sellers. The pace and nature of these deals suggests that there are more to come in the next several years.


Jim Miller
PharmSource has counted at least 20 acquisitions of CMC service providers in 2012 through the end of November 2012 (see Table I). Some of the larger and more significant deals are listed in the accompanying table. There seem to be a wide variety of underlying drivers for the acquisition activity, but several really stand out.

Size matters


Table I: Select mergers and acquisitions in the contract-services industry, 2012*
Arguably, the most important of these drivers has been the pursuit of large size. Company size and breadth of capabilities has clearly been a major criterion in the awarding of strategic sourcing relationships for clinical research services by global bio/pharmaceutical companies. Size reflects broad scope, financial strength, and the ability to achieve economies of scale. Although the strategic sourcing trend is still evolving in manufacturing, where CMOs are battling with in-house capacity, it has penetrated the clinical packaging and analytical services segments of CMC services, where large companies are clearly favored.

Another advantage of size is that larger companies get the attention of the investor community, which provides investment capital for growth and the opportunity for current owners to realize the value of their investments. Whether the plan is to eventually sell equity to the public, or sell to another private equity firm, the size of a company is important to the investment community, which likes to put large amounts of capital to work in any given deal. Even if a CRO or CMO is a business unit of a larger, diversified company, size is likely to be critical to getting senior management attention and access to corporate capital for investment.

Broader capabilities

Another driver of acquisition activity in 2012 has been the desire of companies to position themselves in segments of the market that promise more robust growth or better margins than more mundane services. Highly desirable opportunities have included services that support development and manufacture of biopharmaceuticals (both APIs and injectable drug products) and drug-delivery technologies that can be broadly applied such as softgels. Examples of deals driven by these considerations include the acquisitions of Banner PharmaCaps and Aenova, both of which are major players in the softgel business, and Sigma Aldrich's acquisition of BioReliance, a market leader in services for development of biologics.

When the objective is to add important capabilities in critical markets, deals can be strategically important even if they are not large. So-called "bolt-on" acquisitions enable CMOs and CROs to add skills and facilities quickly and with immediate payback and are not disruptive to the acquirer's core operations. A recent example is the acquisition of the UK biosafety laboratory Vitrology by SGS Life Sciences, which extended SGS's offerings for the testing of biopharmaceuticals.

A third rationale that has underlain several recent acquisitions has little to do with contract services. CMOs are being acquired to serve as platforms for building generic products businesses. DPT Laboratories, Confab, and Metrics have all been acquired by companies whose ultimate objective is to build a generic or specialty pharmaceutical business by pairing acquired manufacturing capacity with in-licensed or acquired products. Those companies, well-respected in their respective service areas (semisolids and liquids for DPT and Confab, solid dose and analytical for Metrics), will maintain their successful contract services businesses but also will take on more production of proprietary products.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here